日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study

STARBOARD 研究中，恩考拉非尼联合比美替尼和帕博利珠单抗治疗 BRAF V600 突变型黑色素瘤成人患者的初步结果简明摘要

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2488226
Dudnichenko, Oleksandr; Penkov, Konstantin; McKean, Meredith; Mandalà, Mario; Kukushkina, Mariia; Panella, Timothy; Csőszi, Tibor; Gerletti, Paola; Thakur, Mahgull; Poll, Anna; di Pietro, Alessandra; Schadendorf, Dirk
BRAF
黑色素瘤
STAR
发表日期：2025
文献求助 收藏

A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

COLUMBUS 研究第一部分 7 年更新的简明语言摘要：恩考拉非尼和比美替尼治疗 BRAF V600 突变型黑色素瘤患者

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2024.2442851
Schadendorf, Dirk; Dummer, Reinhard; Flaherty, Keith T; Robert, Caroline; Arance, Ana; de Groot, Jan Willem B; Garbe, Claus; Gogas, Helen J; Gutzmer, Ralf; Krajsová, Ivana; Liszkay, Liszkay; Loquai, Carmen; Mandalà, Mario; Yamazaki, Naoya; Queirolo, Paola; Guenzel, Carolin; Polli, Anna; Thakur, Mahgull; di Pietro, Alessandra; Ascierto, Paolo A
黑色素瘤
BRAF
COL
发表日期：2025
文献求助 收藏

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

阿昔替尼联合帕博利珠单抗治疗晚期肾细胞癌患者：一项 Ib 期试验的长期疗效和安全性

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2020.12.009
Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Tarazi, Jamal C; Duggan, William; Perini, Rodolfo; Thakur, Mahgull; Fernandez, Kathrine C; Choueiri, Toni K
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2021
文献求助 收藏